Drug Trial Radar · NCT06344936
Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
28
Planned (sponsor's estimate)
Start
Apr 2024
Primary completion
Jul 2024
Study completion Jul 2024
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects
Conditions
- Chronic Kidney Disease(CKD)
Interventions
HRS-1780 tablets; Itraconazole capsules; Rifampicin capsulesDrug
Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the Cmax of HRS-1780 in plasma.Time frame: About 3 days after the dose.
- Assess the Tmax of HRS-1780 in plasma.Time frame: About 3 days after the dose.
- Assess the t1/2 of HRS-1780 in plasma.Time frame: About 3 days after the dose.
- Assess the AUC0-t of HRS-1780 in plasma.Time frame: About 3 days after the dose.
- Assess the AUC0-inf of HRS-1780 in plasma.Time frame: About 3 days after the dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.